What is 20/20 Biolabs, Inc. (AIDX) stock price today?

20/20 Biolabs, Inc. (AIDX) is currently trading at $0.38, down 1.06% today.

What is AIDX P/E ratio?

20/20 Biolabs, Inc.'s P/E ratio is -0.46. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is AIDX return on equity (ROE)?

20/20 Biolabs, Inc.'s return on equity (ROE) is -387.27%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is 20/20 Biolabs, Inc.'s market cap?

20/20 Biolabs, Inc. has a market capitalization of $4.59M.

NCM · Medical - Care Facilities

20/20 Biolabs, Inc. (AIDX) Stock

$0.38 -1.06% NCM: AIDX Healthcare

Valuation

Metric	Value
Price	$0.38
Market Cap	$4.59M
P/E Ratio	-0.46
P/B Ratio	1.20
P/S Ratio	2.12
EPS (TTM)	$0.00
52-Week High	$50.00
52-Week Low	$0.33
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-387.27%
ROA	-94.96%
ROCE	-123.20%
Gross Margin	-162.89%
Operating Margin	-162.89%
Net Margin	-285.00%
Debt/Equity	0.18
Current Ratio	0.60

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$10.0M	$11.0M	$1.0M	$2.0M	$2.0M
Operating Profit	$2.0M	$2.0M	$-6.0M	$-6.0M	$-3.0M
Net Profit	$2.0M	$2.0M	$-6.0M	$-6.0M	$-4.0M
EPS	$0.22	$0.23	$-1.34	$-1.16	$-0.60
Op Margin	20.2%	15.2%	-446.6%	-323.1%	-162.9%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$10.0M	$12.0M	$6.0M	$4.0M	$4.0M
Total Liabilities	$3.0M	$3.0M	$2.0M	$2.0M	$4.0M
Cash	$3.0M	$9.0M	$4.0M	$2.0M	$1.0B
Borrowings	$2.0M	$2.0M	$2.0M	$2.0M	$1.3B

Latest News

20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy GlobeNewswire · Jul 27, 2026 20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock GlobeNewswire · Jul 23, 2026 20/20 BioLabs Highlights Investor Webinar Focused on OneTest™ for Medicare, Serial Biomarker Tracking, and Strong Q2 Revenue Growth GlobeNewswire · Jul 9, 2026 20/20 BioLabs Announces Monthly Investor Webinar Series to be Held on the First Wednesday of Each Month GlobeNewswire · Jun 22, 2026 20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters GlobeNewswire · May 27, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-1.0M	$6.0M	$-5.0M	$-3.0M	$-1.9B
Investing Cash Flow	$0	$-1.0M	$0	$0	$0
Financing Cash Flow	$0	$0	$0	$0	$1.2B
Net Cash Flow	$0	$5.0M	$-5.0M	$-2.0M	$-758.0M
Free Cash Flow	$-1.0M	$6.0M	$-5.0M	$-3.0M	$-1.9B

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.01
EV / EBITDA	-0.07
FCF Yield	-64.54%
Quick Ratio	1.95
Interest Coverage	-6.34
Return 1Y	—
Return 3Y	—
Return 5Y	—

Ownership

Insiders Held26.16%

Institutions Held2.73%

Institutions Float Held3.69%

Institutional Holder	Shares	Report Date
Cresset Asset Management, LLC	264,368	2026-03-31
Citadel Advisors Llc	16,227	2026-03-31
Xtx Topco Ltd	10,329	2026-03-31
UBS Group AG	8,314	2026-03-31
McDonald Partners LLC	2,800	2026-06-30

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AAPLApple Inc.	$336.64	-1.11%	38.93	$4.94T	0.32%
MSFTMicrosoft Corporation	$535.07	+2.38%	28.68	$3.97T	0.76%
GOOGLAlphabet Inc.	$351.66	+0.97%	16.94	$4.26T	0.26%
AMZNAmazon.com, Inc.	$262.43	+3.29%	19.82	$2.82T	0.00%
METAMeta Platforms, Inc.	$718.67	-0.31%	27.93	$1.83T	0.28%

About 20/20 Biolabs, Inc.

20/20 Biolabs, Inc. is led by CEO Jonathan Cohen, employs 13 people, headquartered in US, publicly traded since 2023.

20/20 Biolabs, Inc. (AIDX) stock trades at $0.38 with a market capitalization of $4.59M. The stock is valued at a price-to-earnings (P/E) ratio of -0.46, price-to-book of 1.20, price-to-sales of 2.12. Over the past 52 weeks the stock has ranged between $0.33 and $50.00, and currently trades 99.2% below its 52-week high.

On profitability, 20/20 Biolabs, Inc. generates a return on equity (ROE) of -387.27%, return on capital employed of -123.20%, an operating margin of -162.89%, a net profit margin of -285.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks All stock screens

Run Stock Screener Investing Guides